Last updated on October 2017

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease


Brief description of study

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Detailed Study Description

The primary objective of the study is to evaluate the efficacy of monthly doses of Aducanumab in slowing cognitive and functional impairment.

Clinical Study Identifier: TX153658

Contact Investigators or Research Sites near you

Start Over

Jennifer Cavin

NeuroStudies
Decatur, GA USA
  Connect »